Polysorbate In Biopharma Market - Forecast(2024 - 2030)

Polysorbate In Biopharma market size market was estimated at $112.4 million in 2020, growing at a CAGR of 7.2% during the forecast period 2021-2026. Polysorbates are non-ionic surfactant and emulsifier widely used in pharmaceutical application owing to its nontoxicity, easy accessibility, emulsification and solubilisation properties. Polysorbates are fatty acid and sorbitan-based oily liquids. They are made when sorbitol and polyol react with ethylene oxide. The function of polysorbate is to disperse oil in water rather than water in oil. There are two types of polysorbate such as polysorbate 20 and polysorbate 80. Polysorbates are widely used in protein therapy medicines because of their ability to suppress protein aggregation, perhaps via reducing protein accumulation and subsequent aggregation at the interface. Increasing application of polysorbate In biopharmaceutical application to prepare several vaccines such as influenza, Hepatitis B, HPV, meningococcus and Covid-19 vaccines is the major factor driving the growth of the market. Increasing usage of polysorbate as stabilizing drug coupled with rising demand of polysorbate to prevent aggregation of protein is set to further enhance the overall market development of the Polysorbate In Biopharma Market for the period 2021-2026.

The report: “Polysorbate In Biopharma Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Polysorbate In Biopharma Market.

By Type: Polysorbate 20 and Polysorbate 80

By Function: Excipient, Membrane Protein Solubilizing Agent and Washing Agent

By Biopharmaceutical Product: Monoclonal Antibodies, Recombinant Growth Factors, Vaccines, and Gene Therapy

By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), and Rest of the World (Middle East, Africa and South America)

Based on type, the polysorbate In biopharma market is segmented into polysorbate 20 and polysorbate 80. Polysorbate 80 held the largest share and also it is estimated to register higher CAGR of 8.2% during the forecast period 2021-2026. Polysorbate 80 is a nonionic synthetic surfactant used in biopharmaceutical preparations as an excipient. Some of the drugs manufactured with polysorbate 80 are docetaxel, epoetin/darbepoetin, and fosaprepitan, used in cancer treatment for chemotherapy, supportive care, or prophylaxis thereby increasing polysorbate In biopharma market.

Based on function, the polysorbate In biopharma market is segmented into Excipient, Membrane Protein Solubilizing Agent and Washing Agent. Excipient held the largest share and also it is estimated to register higher CAGR of 7.9% during the forecast period 2021-2026. An excipient is a pharmacologically inactive substance made with the medicinal component of a drug. They help with absorption and solubility of medications, as well as other pharmacokinetic concerns. Polysorbate 20 and Polysorbate 80 are used in vaccines, as an excipient during the production of antigen preparation thereby increasing the demand of polysorbate In biopharma market.

North-America dominated the Polysorbate In Biopharma market with a major share of 41.2% in 2020. This is owing to increasing demand of Polysorbate as an excipient in Biopharmaceutics, where it is utilized to stabilize aqueous formulations of drugs for parenteral administration or vaccines. Furthermore, growing demand of polysorbate in COVID-19 vaccines which are contributing to the growth of the market in this region.

 

However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to technological advancement in cancer monoclonal antibodies coupled with favorable R&D activities by industry in this region contributing to the growth in this region. Increasing cancer cases in this region is resulting into higher demand of polysorbate is also increasing the growth of the market in this region.

Increasing usage of polysorbate in monoclonal antibodies is increasing the growth of the Polysorbate In Biopharma Market. Monoclonal antibodies (MAbs) are widely utilized as therapeutic proteins, and they undergo a lot of stress during production and delivery. MAbs narrow out when shear rates increase. Furthermore, rising demand of polysorbate 20 and polysorbate 80 in monoclonal antibodies thereby increasing the growth of the Polysorbate In Biopharma market during the forecast period 2021-2026.

Increasing application of polysorbate as excipients in biopharmaceutical formulation is increasing the growth of the Polysorbate In Biopharma market. Furthermore, Polysorbates are non-ionic surfactants that are extensively utilised in the formulation of oral, topical, and injectable medical treatments. Polysorbate 20 and 80 are mostly used excipients is driving the growth of market. Polysorbate 80 and 20 are either employed in vaccines as an excipient or emulsifying agent in the emulsion adjuvants during manufacture of antigen preparation thereby increasing the growth of the Polysorbate In Biopharma Market during the forecast period 2021-2026.

Major factor that is set to impede the growth of the Polysorbate In Biopharma market is side effects of polysorbate as polysorbate 80 has been linked to a variety of systemic responses (e.g., hypersensitivity, nonallergic anaphylaxis, rash). Another factor which hamper the growth of market is effects of polysorbate in protein instability.

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Polysorbate In Biopharma Market. In 2020, the Polysorbate In Biopharma Market share is consolidated by the top ten players present in the market. The Polysorbate In Biopharma Market, top 10 companies are, Lonza, Avantor Inc., Merck KGaA, NOF Corporation, Thermo Fisher Scientific Inc., Guangdong Runhua Chemistry Co., Ltd., Aceto Corporation, Seppic SA, Croda International plc., and Nanjing Well Pharmaceutical Co. ltd.

In April 2021, Lonza signed agreement with aTyr Pharma, Inc. for the manufacture of ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2).